Research and Markets has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H2 2016" report to their offering.
Pulmonary Arterial Hypertension pipeline therapeutics constitutes close to 62 molecules. Out of which approximately 58 molecules are developed by Companies and remaining by the Universities/Institutes.
Our latest report Pulmonary Arterial Hypertension - Pipeline Review, H2 2016 outlays comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Pulmonary Arterial Hypertension Pulmonary arterial hypertension is increased pressure in the pulmonary arteries. These arteries carry blood from heart to lungs to pick up oxygen. Pulmonary arterial hypertension (PAH) is one form of pulmonary hypertension. Symptoms include fatigue, dizziness or fainting spells, chest pressure or pain, swelling (edema) in ankles and legs and shortness of breath (dyspnea). Treatment includes anticoagulant, diuretics and vasodilators. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 8, 11, 31 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/f72cff/pulmonary
View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006413/en/Business Wire
Last updated on: 20/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.